CN105636584A - Method for use of vitamin b composition to promote motility of gastrointestinal system - Google Patents
Method for use of vitamin b composition to promote motility of gastrointestinal system Download PDFInfo
- Publication number
- CN105636584A CN105636584A CN201480039758.4A CN201480039758A CN105636584A CN 105636584 A CN105636584 A CN 105636584A CN 201480039758 A CN201480039758 A CN 201480039758A CN 105636584 A CN105636584 A CN 105636584A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- composition
- acid
- biotin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 229940088594 vitamin Drugs 0.000 title claims description 76
- 229930003231 vitamin Natural products 0.000 title claims description 76
- 235000013343 vitamin Nutrition 0.000 title claims description 76
- 239000011782 vitamin Substances 0.000 title claims description 76
- 150000003722 vitamin derivatives Chemical class 0.000 title claims description 68
- 230000004899 motility Effects 0.000 title abstract description 5
- 210000005095 gastrointestinal system Anatomy 0.000 title abstract description 3
- 238000000034 method Methods 0.000 title description 20
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 90
- 239000011720 vitamin B Substances 0.000 claims abstract description 90
- 230000002265 prevention Effects 0.000 claims abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 116
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 113
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 97
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 79
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 78
- 229960003512 nicotinic acid Drugs 0.000 claims description 77
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 77
- 229960003495 thiamine Drugs 0.000 claims description 77
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 75
- 229960002477 riboflavin Drugs 0.000 claims description 75
- 229940046001 vitamin b complex Drugs 0.000 claims description 56
- 235000020958 biotin Nutrition 0.000 claims description 49
- 229960002685 biotin Drugs 0.000 claims description 48
- 239000011616 biotin Substances 0.000 claims description 48
- 235000019152 folic acid Nutrition 0.000 claims description 40
- 239000011724 folic acid Substances 0.000 claims description 40
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 40
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 40
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 39
- 229930003451 Vitamin B1 Natural products 0.000 claims description 39
- 229960000304 folic acid Drugs 0.000 claims description 39
- 235000001968 nicotinic acid Nutrition 0.000 claims description 39
- 239000011664 nicotinic acid Substances 0.000 claims description 39
- 235000019157 thiamine Nutrition 0.000 claims description 39
- 235000010374 vitamin B1 Nutrition 0.000 claims description 39
- 239000011691 vitamin B1 Substances 0.000 claims description 39
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 38
- 229930003537 Vitamin B3 Natural products 0.000 claims description 38
- 235000019192 riboflavin Nutrition 0.000 claims description 38
- 239000002151 riboflavin Substances 0.000 claims description 38
- 239000011721 thiamine Substances 0.000 claims description 38
- 235000019160 vitamin B3 Nutrition 0.000 claims description 38
- 239000011708 vitamin B3 Substances 0.000 claims description 38
- 235000019158 vitamin B6 Nutrition 0.000 claims description 38
- 239000011726 vitamin B6 Substances 0.000 claims description 38
- 229940011671 vitamin b6 Drugs 0.000 claims description 38
- 229930003471 Vitamin B2 Natural products 0.000 claims description 37
- 235000019164 vitamin B2 Nutrition 0.000 claims description 37
- 239000011716 vitamin B2 Substances 0.000 claims description 37
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 claims description 36
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 30
- 206010010774 Constipation Diseases 0.000 claims description 25
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 25
- 229960004874 choline bitartrate Drugs 0.000 claims description 25
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 25
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 25
- 229960000367 inositol Drugs 0.000 claims description 25
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 25
- 229930003779 Vitamin B12 Natural products 0.000 claims description 21
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 21
- 235000019163 vitamin B12 Nutrition 0.000 claims description 21
- 239000011715 vitamin B12 Substances 0.000 claims description 21
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 17
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
- 229960001231 choline Drugs 0.000 claims description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
- 150000004001 inositols Chemical class 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 7
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 6
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000001288 gastroparesis Diseases 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229960002428 fentanyl Drugs 0.000 claims description 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 229960001797 methadone Drugs 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- -1 vitamin compound Chemical class 0.000 claims description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 3
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 3
- 229960000240 hydrocodone Drugs 0.000 claims description 3
- 229960002085 oxycodone Drugs 0.000 claims description 3
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- 208000013617 idiopathic gastroparesis Diseases 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 235000000638 D-biotin Nutrition 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 abstract description 34
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 29
- 238000003304 gavage Methods 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 229960001571 loperamide Drugs 0.000 description 25
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 25
- 230000013872 defecation Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 239000000976 ink Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 9
- 230000002040 relaxant effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229960004127 naloxone Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001141 propulsive effect Effects 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000030136 gastric emptying Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229940055726 pantothenic acid Drugs 0.000 description 3
- 235000019161 pantothenic acid Nutrition 0.000 description 3
- 239000011713 pantothenic acid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- QQQIECGTIMUVDS-UHFFFAOYSA-N N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NCC1=CC=C(OCCN(C)C)C=C1 QQQIECGTIMUVDS-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 229960005302 itopride Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
- 101710161460 3-oxoacyl-[acyl-carrier-protein] synthase Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000014653 neuromuscular process Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a vitamin B composition, and in particular to a vitamin B composition promoting motility of the gastrointestinal system. The present composition is suitable for the prevention and/or treatment of conditions or ailments related to deficiencies of gastrointestinal motility.
Description
Promote the method for gastronintestinal system power using vitamin B composition
Technical field
The present invention relates to a kind of vitamin B composition, especially a kind of vitamin B composition of promotion gastronintestinal system power.Said composition is applied to prevention and/or treated and gastroenteritic power deficient related state or disease.Background technology
Now, people's life stress is generally increased, and rhythm of life is accelerated, and increasingly competitive, gastrointestinal distress or upset,gastro-intestinal person are more and more, and its cause is many, and its symptom is also had nothing in common with each other.
Stomach and intestine（Gastrointestinal, GI) power be via digestive system convey nutrients coordination neuromuscular process.It may participate in GERD, gastroparesis（For example, diabetic keratopathy and postoperative gastroparesis）, IBS（IBS), intestinal obstruction and constipation（For example, feature or drug-induced constipation）Gastronintestinal system power to weaken be one of maximum health care burden of industrialized country.In view of the foregoing, effectively facilitate gastronintestinal system power be need badly and by as the progress in this area.
Functional dyspepsia FD（Fimctional dyspepsia) and chronic gastritis often have a symptoms such as abdominal fullness sense, epigastric pain, nausea, anorexia, gastrointestinal tract dyskinesis cause gastric emptying to be the major reason that this kind of symptom occurs.And gastrointestinal tract dyskinesis are easily caused IBS.Now the medicine for the treatment of gastroenteritic power has Metoclopramide, domperidone and Itopride.
The medicine for the treatment of gastrointestinal disease was many in the past, but the good effect and person of having no side effect is very few, can especially make long-term care effect, but improve very well gastrointestinal function promote gastroenteritic power and slow down upset,gastro-intestinal symptom medicine or health products it is even more few.
As described above（1) Metoclopramide, the medicine is dopamine receptor blockade medicine, with powerful central town Tuhe intestines and stomach excitation.The medicine can suppress pipe smooth muscle relaxation, gastrointestinal smooth muscle is increased cholinergic reaction, rapid gastric emptying, increase antrum portion phase activity.In addition, the medicine still irritates lactogen release.The more typical lethargic sleep of side effect of Metoclopramide, dysphoria, lassitude, the another medicine is heavy dose of or prolonged application may show as the symptom of parkinsonism because blocking dopamine receptor.（2) domperidone is periphery property dopamine-receptor antagonist, the wriggling and tension force of on the gastrointestinal tract can be promoted to recover normal, promote gastric emptying, increase antrum and duodenum bowel movement, coordinate the contraction of pylorus, while can also strengthen the wriggling of esophagus and the tension force of esophageal sphincter.Because it is poor to the penetration of blood-brain barrier, to intracerebral dopamine receptor almost without antagonism, the external report for thering is vein large bolus injection to cause epileptic attack（The country is without this preparation）, but the medicine is a kind of strong lactogen release medicine, may cause menstrual disorder.（3) double action of the retardance of Itopride tool dopamine receptor and acetylcholine ester enzyme level, discharge by irritating endogenous acetylcholine and suppresses its hydrolysis and strengthen stomach and uodenal movement, promote gastric emptying, and have the effect of telling of moderate town.Old or elderly patient uses this medicine with caution.
Vitamin B is all water soluble vitamin, and majority is coenzyme, participates in the metabolism of sugar, protein and fat in vivo.
Vitamin B1 (thiamine）The effect of cholinesterase activity can be suppressed, be deficient in vitamin B1 when this enzymatic activity it is too high, acetylcholine（One of neurotransmitter）Considerable damage makes nerve conduction be affected, and may involve the secretion of gastrointestinal motility and digestive juice.Thiamines would generally be made as the relatively stable form such as hydrochloride or nitrate to use
(riboflavin 1 constitutes many important coenzyme to vitamin B2, participates in metabolism and releases energy：Help grows.It can maintain and improve
The health of epithelial tissue, such as alimentary canal mucous membrane tissue.
Vitamin B3 (nicotinic acid）The coenzyme of dehydrogenase is constituted in vivo, vitamin B3 is the most persons of human body requirement in B family vitamin, it does not maintain the vitamin of digestive system health still, can mitigate gastrointestinal disorders yet.Nicotinic acid is converted into niacinamide in human body, and niacinamide is DPN and DPN I part, participates in HypercholesterolemicRats, the oxidizing process of tissue respiration and the process of carbohydrate anaerobic decomposition.
Vitamin B5 (pantothenic acid）Activity form be coacetylase, be acyl carrier in vivo, the symptom for the B5 that is deficient in vitamin has poor appetite, indigestion, is susceptible to suffer from duodenal ulcer.
Vitamin B6 includes 3 kinds of pyridoxol, pyridoxal and pyridoxamine, can mutual inversion of phases.Studies have reported that vitamin B6 can mitigate azithromycin to gastrointestinal side effect with azithromycin mixing intravenous infusion.
Deoxyadenosyl cobalamin is that vitamin B12 is primarily present form in vivo.The effect of it and folic acid is often interrelated.Folic acid has a variety of auxiliary chest forms in cell, has research prompting folic acid to have intervention effect, folate treatable atrophic gastritis, improvement pathology of gastric mucosa to gastrointestinal cancer.
Biotin side chain carboxyl group can be connected by amido link with the lysine residue of enzyme.Biotin is carboxyl carrier, also participates in vitamin B12, folic acid, the metabolism of pantothenic acid.
Choline bitartrate, which has, promotes phosphatide transformation, the operating for accelerating fat and choleretic effect；Inositol can promote cell metabolism, foster growth, improve a poor appetite.P-aminobenzoic acid（PABA) be actually folic acid a kind of composition, its effect in vivo is coenzyme, and it works to promote the metabolism of protein and the generation of haemocyte together with folic acid.
From mechanism of action, vitamin B would be possible to turn into a kind of medicine or health food of the new promotion gastronintestinal system power with higher-security, but up to the present also prove facilitation of the vitamin B to gastronintestinal system power without factual evidence, particularly under pathological state, treatment and adjustment effect of the vitamin B to gastronintestinal system motility disorder.Additionally, due to vitamin B, family member is numerous, and there is complementary relation, thus vitamin B into component selections and compatibility, treated or the medicine or health food of regulation gastronintestinal system motility disorder are most important for preparing.The content of the invention
A. summary of the invention
The present invention relates to the method for promoting gastronintestinal system power in the object for having this needs, wherein the object suffers from gastrointestinal system disorder（That is, dysfunction caused by deficiency disorder, illness, symptom or medicine or operation）.This method includes applying the vitamin B complex composition of therapeutically effective amount to the object for having this needs.Signified vitamin includes its corresponding analog or derivative in the present invention, and such as vitamin B1 refers to thiamine and its analog or derivative；Vitamin B2 refers to riboflavin and its analog or derivative；Vitamin B3 refers to nicotinic acid and its analog or derivative；Vitamin B5 refers to pantothenic acid and its analog or derivative；Vitamin B6 refers to pyridoxol and its analog or derivative；Vitamin B7 is biotin and its analog or biology；Vitamin Β 9 refers to folic acid and its analog or derivative；Vitamin B12 refers to cyanocobalamin and its analog or derivative；Etc..In a preferred embodiment, vitamin Β races composition is to include vitamin B1 (thiamine）, (the riboflavin of vitamin Β 2）, (the nicotinic acid of vitamin Β 3）, (the pantothenic acid of vitamin Β 5）, vitamin Β 6, the composition of biotin.In a preferred implementation
In scheme, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3
(nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
On the other hand, the invention provides a kind of composition, said composition includes the vitamin B complex composition and pharmaceutically acceptable carrier of effective dose.In a preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, biotin and pharmaceutically acceptable carrier.In a further preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, inositol and pharmaceutically acceptable carrier.In another further preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, inositol, p-aminobenzoic acid and pharmaceutically acceptable carrier.
On the other hand, the present invention relates to a kind of composition, said composition includes the vitamin B complex composition of effective dose and the treatment of effective dose and/or the medicine for preventing gastrointestinal disease.In a preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the treatment of biotin and effective dose and/or the medicine for preventing gastrointestinal disease.In a further preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the treatment of inositol and effective dose and/or the medicine for preventing gastrointestinal disease.In another further preferred embodiment, said composition includes vitamin B1 (thiamine), the vitamin B2 (riboflavin of effective dose）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, inositol, the treatment of p-aminobenzoic acid and effective dose and/or the medicine for preventing gastrointestinal disease.
On the other hand, the present invention relates to a kind of composition, said composition includes the vitamin B complex composition of effective dose and the group vitamins compound of other effective dosies.In a preferred embodiment, said composition includes the vitamin B1 (thiamine of effective dose）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the group vitamins compound of biotin and other effective dosies.In a further preferred embodiment, said composition includes vitamin B1 (thiamine), the vitamin B2 (riboflavin of effective dose）, vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the group vitamins compound of inositol and other effective dosies.In another further preferred embodiment, said composition includes vitamin B1 (thiamine), vitamin B2 (riboflavin), the vitamin B3 (nicotinic acid of effective dose）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, inositol, the group vitamins compound of p-aminobenzoic acid and other effective dosies.Other described group vitamins compounds include compound and its analog or the derivatives such as vitamin eight, vitamin C, vitamin D, vitamin E, vitamin K.
Gastroenteritic power is promoted to be used to treat drug-induced gastrointestinal dysfunction in the object for have this needs（For example, intestinal dysfunction that opioid drug, such as morphine cause or constipation）Method in, this method include apply therapeutically effective amount dimension give birth to
Plain B races composition.The object can carry out postoperative pain control using opioids or opioid or chronic ache is controlled.The example of opioids and opioid includes morphine, codeine, Oxycodone, hydrocodone（hydrocod0ne), methadone（Methadone), fentanyl（) and itself and antiinflammatory fentanyl（Such as paracetamol or aspirin）Combination.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine), vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
Gastroenteritic power is promoted to can be used for treating gastroparesis in the object for having this needs, it passes through the vitamin B race composition using therapeutically effective amount.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid), vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
In another embodiment, gastroenteritic power is promoted to be used in the object for have this needs treat GERD（Gastro esophageal reflux disease, GERD) method in, this method include apply therapeutically effective amount vitamin B complex composition.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3
(nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2
(riboflavin）, vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.In a specific embodiment, the GERD is nocturnal gastroesophageal reflux disease.
Present invention also offers promote gastroenteritic power in the object for having this needs to treat IBS（Irritable bowel syndrome, IBS) method, it is realized by applying the vitamin B complex composition of therapeutically effective amount.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3
(nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）、
Vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.The IBS can be constipation-predominant of irritable bowel syndrome or constipation/diarrhoea alternate type IBS.
Present invention also offers method of the gastroenteritic power to treat constipation is promoted in the object for having this needs, it is realized by applying the vitamin B complex composition of therapeutically effective amount.The constipation includes feature（Bad life habits, eating habit, senile constipation of the grade without organic cause）With drug-induced constipation.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin), vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
In one embodiment, promotion gastroenteritic power be used to treat in the object for have this needs is caused or related gastrointestinal dysfunction by operation（For example postoperative intestine is wriggled and slowed down）Method in, this method include apply therapeutically effective amount vitamin B race composition.In a preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.In a further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
It is preferred that vitamin B complex composition be include vitamin B1 (thiamine), vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, the composition of biotin.Preferred vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, folic acid, biotin, choline bitartrate, the composition of inositol.In another further preferred embodiment, vitamin B complex composition is to include vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6, vitamin B12, folic acid, biotin, choline bitartrate, the composition of inositol and p-aminobenzoic acid.
The formulation of the vitamin B complex composition of the present invention can be chewable tablet, but not limited to this, the present composition can also add various customary adjuvants required when preparing different dosage forms, such as disintegrant, lubricant, adhesive, antioxidant, complexing agent pharmaceutical carrier, any conventional peroral dosage form, such as other formulations of dispersible tablet, granule, capsule, oral liquid are made with conventional formulation method.
The vitamin B complex composition of the present invention, the weight proportion of its each component can have multiple choices, and it has corresponding facilitation to gastronintestinal system power.In certain embodiments, it can include the component of following weight proportion：10 parts of vitamin B l,
10-15 parts of vitamin B2s, 6-25 parts of vitamin B3s, 10-100 parts of vitamin B5s, 5-10 parts of vitamin B6s and 0.01-0.1 parts of biotins.In a preferred embodiment, vitamin B complex composition includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s and 0.1 part of biotin.In a further preferred embodiment, vitamin B complex composition includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates and 250 parts of inositols.In another further preferred embodiment, vitamin B complex composition includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates, 250 parts of inositols, 0.025 part of vitamin B12 and 50 parts of p-aminobenzoic acid.
B. define
Except as otherwise definition, all scientific and technical terminologies used herein understand that implication is identical with general technical staff of the technical field of the invention.All patent documents, Patent Application Publication, disclosed patent document and other publications are as reference.This section illustrate definition with above-mentioned bibliography as described in definition it is inconsistent or opposite when, be defined by the definition that this section is illustrated.
Unless clearly indicated that within a context, " one " as used herein means " at least one " or " one or more than one ".
Term " part ", more particularly to one given amount, refers to amount of the positive and negative deviation within 10%.Term used herein " is included（Comprises) ", " include（Comprising) ", " include（Includes) ", " include（Including) ", " contain（Contains),, " contain（Containing) " and its any variant is intended to non-monopolistic inclusion, for example including, include or contain the composition of process, method, converted products or the material of a kind of element or the element of a list not only includes intrinsic other elements that those elements are also possible that the composition of the do not list clearly or process, method, converted products or material.Terminology used herein " vitamin B complex composition " includes all vitamin B compounds, its analog or derivative, such as vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid）With vitamin B6 etc..Terminology used herein " analog " refers to that structure is roughly the same and has identical bioactivity but can have different degrees of active any two above molecule or wherein fragment.Term " derivative " used refers to that hydrogen atom or atomic group in compound are replaced and derivative more complicated compound by other atoms or atomic group.
Embodiment
The vitamin B complex composition specific formula of embodiment 1
Vitamin B complex composite formula 1 includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s and 0.1 part of biotin.Vitamin B complex composite formula 2 includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates and 250 parts of inositols.Vitamin B complex composite formula 3 includes the component of following weight proportion：10 parts of vitamin B l, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates, 250 parts of inositols, 0.025 part of vitamin B12 and 50 parts of p-aminobenzoic acid.Vitamin B complex composite formula 4 includes the component of following weight proportion：10 parts of vitamin B1s, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates, 250 parts of inositols and 0.025 part of vitamin B12.
The vitamin B complex composition of embodiment 2 causes the therapeutic action of mice with constipation to Loperamide
1. experiment material
1.1 medicine
Vitamin B complex composition（VB 1) is formulated, 2 and formula 3 are formulated
Loperamide（Loperamide):Sigma companies, lot number： 109K1107V
Naloxone：Beijing Sihuan Pharmaceutical Co., Ltd, lot number： 20110505
1.2 animal
C57BL/6 mouse, female, 18 ~ 22g of body weight
2. experimental method
The preparation of 2.1 prepared Chinese ink：
Arabic gum 100g accurately is weighed, add water 800ml, boil transparent to solution, weighed activated carbon powder 50g and add and boiled 3 times in above-mentioned solution, the constant volume that added water after solution is cool is to 1000ml.
2.2 Loperamides cause Constipated mice to prepare
Loperamide is with 1% Tween 80 physiological saline solution, and mouse was to fasting before Loperamide 24 hours（It can't help water）Afterwards, it is disposable that the Loperamide for giving that dosage is 5mg/kg is subcutaneously injected.After 30 minutes, gavage gives prepared Chinese ink.Administered volume is 10ml/kg.2.3 packets and administration
To 60 minutes before prepared Chinese ink, administration group gavage gave VB, and positive controls gavage gives naloxone, and other groups are given physiological saline.
Administered volume is 20ml/kg body weight.
Control group：Gavage gives normal saline
Model group：Gavage gives normal saline
Naloxone group：Gavage gives naloxone 50mg/kg
Each dosage group：Gavage is given (is converted into the amount of mouse according to formula 1-3）
2.4 observation item
After gavage gives prepared Chinese ink 20 minutes, de- cervical vertebra puts to death animal, abdominal cavity separation mesenterium is opened immediately, intestinal tube of the clip upper end from pylorus, lower end to ileocecus, it is placed on pallet, small intestine is gently pulled into straight line, measures total small intestinal length, length is promoted from pylorus to prepared Chinese ink forward position for prepared Chinese ink, small intestine ink progradation is calculated.
3. experimental result
Each formulation data is as follows：
Group body weight (g) small intestinal length (cm) prepared Chinese ink advance distance (cm) Intestinal propulsive rate (%) model group（n=8) 16.5±0.7 19.3±1.6 5.7±0.7 29.9±5.5
Naloxone group（n=8) 16.1±0.4 16.8±1.5** 7.6±1.7* 44.8±8.1**
It is formulated 3 30.8mg/kg (n=8) 16.3 ± 07 19.8,41.9 ± 5.7** of ± 1.2 8.3 ± 1.0**
It is formulated 3 153.8mg^g (n=8) 16.4 ± 0.3 19.9,42.6 ± 9.2** of ± 1.7 9.2 ± 2.1**
It is formulated 3 768.7mg kg (n=8) 16.3 ± 0.9 20.1,43.8 ± 10.5** of ± 1.3 9.6 ± 2.2**
Normal group（n=8) 16.3±0.7 19.3±1.8 11.8±2.7** 61.2±11.3**
*：Compared with model group, P<0.05; **：Compared with model group, PO.01
It can be seen that from data above, formula 1-3 has corresponding facilitation to the gastroenteritic power of mouse, and be in increasing trend with the increase of application dosage.The vitamin Β race's compositions of embodiment 3 cause the influence of mice with constipation bowel relaxing functions to Loperamide
1. experiment material
1.1 medicine
Vitamin Β races composition（VB 3) are formulated
Loperamide（Loperamide):Sigma companies, lot number：The animals of 109K1107V 1.2
C57BL/6 mouse, male, the 24g of body weight 18
2. experimental method
Influence of 2.1 vitamin B compounds to normal mouse bowel relaxing functions
Mouse is randomly divided into four groups, and administration group gavage gives compound VB formulas 3, and other groups are given drinking water.Administered volume is 20ml/kg body weight.
Vitamin B compound group low dose group（A groups）：Normal mouse gavage gives VB formula 3 153.8mg/kg (n=14) vitamin B compound group middle dose groups（B groups）：Normal mouse gavage gives VB formula 3 768.7mg/kg (n=14) vitamin B compound group middle dose groups（C groups）：Normal mouse gavage gives VB formula 3 3843.7mg/kg (n=14) normal groups（D groups）：Normal mouse gavage gives equivalent drinking water（n=14)
Administration terminates to start after timing, timing 7hl5min, takes off cervical vertebra and puts to death animal, records body weight, body weight at the end of experiment, 7hl5min defecation quantity and defecation dry weight before every mouse administration（60°C,6h).
2.2 vitamin B compounds cause the influence of mice with constipation bowel relaxing functions to normal mouse and Loperamide
Mouse is randomly divided into three groups, and administration group gavage gives compound VB formulas 3, and other groups are given drinking water.Administered volume is 20ml/kg body weight.
Model group（A groups）：Mice with constipation gavage gives equivalent drinking water（n=10)
Vitamin B compound group（B groups）：Mice with constipation gavage gives VB and is formulated 3 768.7mg/kg (n=10)
Control group（C groups）：Normal mouse gavage gives equivalent drinking water（n=10)
It is administered after 60min and uses Loperamide gavage modeling.Loperamide drinking water dissolves, and gavage gives dosage for 4mg/kg, administration
Volume is 10ml/kg.After modeling 15 minutes, start timing, mouse single cage word is supported, and water is can't help in fasting.After timing 6h, take off cervical vertebra and put to death animal, record body weight, body weight at the end of experiment, 6h defecation quantity and defecation dry weight (60 before every mouse administration.C, 6h).
3. experimental result
Influence of 3.1 vitamin B compounds to normal mouse bowel relaxing functions
A groups are compared with D groups, and defecation grain number is not significantly different, and there were significant differences for defecation dry weight（P<0.05), show that low dosage is combined VB and can dramatically increase the defecation dry weight of mouse, but defecation grain number can not be significantly increased；B groups, C groups are compared with D groups, and there were significant differences for defecation grain number and defecation dry weight（P<0.01, P<0.01 ; P<0.01 , P<0.01), show that compound VB middle dosages and high dose can dramatically increase the defecation quantity and defecation dry weight in normal mouse 7M5min.Germicidal efficacy also found that the appearance of high dose mouse is just dilute simultaneously, thus it is speculated that be probably the toxic side effect for medicine occur.Result data is as follows：
Influence of the various dose vitamin B compound to normal mouse bowel relaxing functions
*：Compared with normal group, PO.05: **：Compared with normal group, PO.01
3.2 vitamin B compounds cause the influence of mice with constipation bowel relaxing functions to normal mouse and Loperamide（For the first time)
C groups are compared with A groups, and there were significant differences for defecation grain number and defecation dry weight（P<0.01, P<0.01), show that Constipated mice is successfully prepared；B groups are compared with A groups, and there were significant differences for defecation grain number and defecation dry weight（PO.01 , P<0.05), show that compound VB can dramatically increase Loperamide and cause defecation quantity and defecation dry weight in mice with constipation 6 hours.Result data is as follows：
*：Compared with model group, Ρ<0.05; **：Compared with model group, Ρ<0.01
3.3 B B-complex Β cause the influence of mice with constipation bowel relaxing functions to normal mouse and Loperamide（Second)
C groups are compared with A groups, and there were significant differences for defecation grain number and defecation dry weight（P<0.01, P<0.01), show that Constipated mice is successfully prepared；B groups are compared with A groups, and there were significant differences for defecation grain number and defecation dry weight（P<0.05, P<0.05), show that compound VB can dramatically increase Loperamide and cause defecation quantity and defecation dry weight in mice with constipation 6 hours.Result data is as follows：
Vitamin B compound causes the influence of mice with constipation bowel relaxing functions to Loperamide（Second)
*：Compared with model group, P<0.05 ; **：Compared with model group, PO.01
As can be seen here, 3 pairs of normal mouses of vitamin B compound formula and Loperamide cause mice with constipation bowel relaxing functions to have significant facilitation.The vitamin B complex composite formula 3 of embodiment 4 and 4 pairs of Loperamides cause the therapeutic action of mice with constipation to compare
1. experiment material
1.1 medicine
Vitamin B complex composition（VB) formula 3 and formula 4
Loperamide（Loperamide):Sigma companies, lot number： 109K1107V
Naloxone：Beijing Sihuan Pharmaceutical Co., Ltd, lot number： 20110505
1.2 animal
C57BL/6 mouse, female, the g of body weight 17 20
2. experimental method
The preparation of 2.1 prepared Chinese ink：
Arabic gum 100g accurately is weighed, add water 800ml, boil transparent to solution, weighed activated carbon powder 50g and add and boiled 3 times in above-mentioned solution, the constant volume that added water after solution is cool is to 1000ml.
2.2 Loperamides cause Constipated mice to prepare
Loperamide is with 1% Tween 80 physiological saline solution, and mouse was to fasting before Loperamide 24 hours（It can't help water）Afterwards, it is disposable that the Loperamide for giving that dosage is 5mg/kg is subcutaneously injected.After 30 minutes, gavage gives prepared Chinese ink.Administered volume is 10ml/kg.2.3 packets and administration
To 60 minutes before prepared Chinese ink, administration group gavage gave VB, and positive controls gavage gives naloxone, and other groups are given physiological saline.Administered volume is 20ml/kg body weight.
Control group：Gavage gives normal saline
Model group：Gavage gives normal saline
Naloxone group：Gavage gives the mg/kg of naloxone 50
Each dosage group：Gavage is given (is converted into the amount of mouse according to formula 3-4）
2.4 observation item
After gavage gives prepared Chinese ink 20 minutes, de- cervical vertebra puts to death animal, abdominal cavity separation mesenterium is opened immediately, intestinal tube of the clip upper end from pylorus, lower end to ileocecus, it is placed on pallet, small intestine is gently pulled into straight line, measures total small intestinal length, length is promoted from pylorus to prepared Chinese ink forward position for prepared Chinese ink, i calculates small intestine ink progradation.
3. experimental result
Each formulation data is as follows：
Various dose VB formulas cause the influence of mice with constipation Intestinal propulsive rate to Loperamide
*：Compared with model group, PO.05; **：Compared with model group, P<0.01 result is shown：Compared with normal group, the Intestinal propulsive rate (%) of model group is significantly reduced（46.9 ± 7.3 VS 15.5 ± 2.8), show that Constipated mice is successfully prepared；Compared with model group, the prepared Chinese ink advance distance and Intestinal propulsive rate (%) of each administration group dramatically increase (p<0.01);It is basically identical that compound VB is formulated 3 and compound VB, 4 action effects in terms of mouse small intestine propulsion rate (%) is improved of formula（25.9±4.5VS24.9±3.7).
Conclusion：Test sample vitamin B compound formula 3 and vitamin B compound formula 4 can significantly improve the Intestinal propulsive rate (%) of the mice with constipation model of Loperamide induction, and the action effect of the two is basically identical.In order to more clearly describe and understand the present invention, the present invention is described in detail in we by way of example, but it will be apparent that those of ordinary skill can make appropriate be altered or modified on the premise of without departing substantially from spirit and scope by the claims to the present invention in the art.
Claims (25)
- Claims1. a kind of vitamin B complex composition, it can be used for prevention and/or treats and gastronintestinal system power deficient related state or disease.2. composition according to claim 1, wherein the vitamin B complex composition includes vitamin B1 (thiamine）, vitamin B2 (riboflavin）, vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid）, vitamin B6 and biotin.3. composition according to claim 1 or 2, wherein the vitamin B complex composition also includes folic acid, choline bitartrate and inositol.4. any combination thing according to claim 1-3, wherein the vitamin B complex composition also includes vitamin B12 and/or p-aminobenzoic acid.5. composition according to claim 1, wherein the gastronintestinal system power scarcity is due to using caused by opioid.6. composition according to claim 5, wherein the opioid is selected from morphine, codeine, Oxycodone, Hydromorphone, hydrocodone, methadone and fentanyl.7. composition according to claim 1, wherein the state or disease include feature or drug-induced constipation, the gastroparesis related to diabetes or idiopathic gastroparesis, GERD, IBS or postoperative intestine are wriggled and slowed down.8. any combination thing according to claim 14, it is characterised in that it includes the vitamin B complex composition and pharmaceutically acceptable carrier of effective dose.9. any combination thing according to claim 14, it is characterised in that its medicine for including the vitamin B complex composition of effective dose and the treatment of effective dose and/or preventing gastrointestinal disease.10. any combination thing according to claim 1-4, it is characterised in that it includes the vitamin B complex composition of effective dose and the vitamin compound of other effective dosies.11. any combination thing according to claim 10, wherein described vitamin compound is selected from vitamin A, C, D, E and K one or more.12. any combination thing according to claim 1-4, it is characterised in that formulation is chewable tablet.13. any combination thing according to claim 1-4, it is characterised in that formulation can also be dispersible tablet, granule, capsule and oral liquid.14. composition according to claim 2, it is characterised in that it includes the component of following weight proportion：10 parts of vitamin B1s, 15 parts of 2,25 parts of vitamin Β, 3,100 parts of vitamin Β vitamin Β, 5,10 parts of vitamin Β 6 and 0.1 part of biotin.15. composition according to claim 3, it is characterised in that it includes the component of following weight proportion：10 parts of vitamin B1s, 15 parts of 2,25 parts of vitamin Β, 3,100 parts of vitamin Β, 5,10 parts of vitamin Β, 6,0.1 part of vitamin Β biotins, 0.4 part of folic acid, 250 parts of choline bitartrates and 250 parts of inositols.16. composition according to claim 4, it is characterised in that it includes the component of following weight proportion：10 parts of vitamin B1s, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates, 250 parts of inositols, 0.025 part of vitamin B12.17. composition according to claim 4, it is characterised in that it includes the component of following weight proportion：10 parts of vitamin B1s, 15 parts of vitamin B2s, 25 parts of vitamin B3s, 100 parts of vitamin B5s, 10 parts of vitamin B6s, 0.1 part of biotin, 0.4 part of folic acid, 250 parts of choline bitartrates, 250 parts of inositols, 0.025 part of vitamin B12 and 50 parts of p-aminobenzoic acid.18. a kind of vitamin B complex composition is preparing treatment and/or prevented and the purposes in the deficient related gastrointestinal condition of gastronintestinal system power or the medicine or health food of disease.19. purposes according to claim 18, wherein the vitamin B complex composition includes vitamin B1 (thiamine）, vitamin B2 (riboflavin), vitamin B3 (nicotinic acid）, vitamin B5 (pantothenic acid）, vitamin B6 and biotin.20. the purposes according to claim 18 or 19, wherein the vitamin B complex composition also includes folic acid, choline bitartrate and inositol.21. any purposes according to claim 18-20, wherein the vitamin B complex composition also includes vitamin B12 and p-aminobenzoic acid.22. purposes according to claim 18, wherein the gastronintestinal system power scarcity is due to using caused by opioid.23. purposes according to claim 22, wherein the opioid is selected from morphine, codeine, Oxycodone, Hydromorphone, hydrocodone, methadone and fentanyl.24. purposes according to claim 18, wherein the state or disease include feature or drug-induced constipation, the gastroparesis related to diabetes or idiopathic gastroparesis, GERD, IBS or postoperative intestine are wriggled and slowed down.25. purposes according to claim 18, wherein described medicine or health food its subject are people.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310327076.0A CN104337813A (en) | 2013-07-23 | 2013-07-23 | Method using vitamin B composition to promote gastrointestinal system motility |
| PCT/CN2014/000712 WO2015010449A1 (en) | 2013-07-23 | 2014-07-28 | Method for use of vitamin b composition to promote motility of gastrointestinal system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105636584A true CN105636584A (en) | 2016-06-01 |
Family
ID=52392667
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911175108.3A Pending CN110840895A (en) | 2013-07-23 | 2013-07-23 | Method for promoting gastrointestinal system motility using vitamin B composition |
| CN201310327076.0A Pending CN104337813A (en) | 2013-07-23 | 2013-07-23 | Method using vitamin B composition to promote gastrointestinal system motility |
| CN201480039758.4A Pending CN105636584A (en) | 2013-07-23 | 2014-07-28 | Method for use of vitamin b composition to promote motility of gastrointestinal system |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911175108.3A Pending CN110840895A (en) | 2013-07-23 | 2013-07-23 | Method for promoting gastrointestinal system motility using vitamin B composition |
| CN201310327076.0A Pending CN104337813A (en) | 2013-07-23 | 2013-07-23 | Method using vitamin B composition to promote gastrointestinal system motility |
Country Status (2)
| Country | Link |
|---|---|
| CN (3) | CN110840895A (en) |
| WO (1) | WO2015010449A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113498862A (en) * | 2021-08-27 | 2021-10-15 | 上海英库商务咨询有限公司 | Diet formula capable of preventing beriberi, herpes and corner inflammation and losing weight |
| CN115105514A (en) * | 2022-06-14 | 2022-09-27 | 邯郸制药股份有限公司 | Pharmaceutical composition for protecting gastric mucosa and treating gastric ulcer and preparation method and application thereof |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| BR112015029293A2 (en) | 2013-05-22 | 2018-04-24 | Zensun Shanghai Science & Tech Ltd | method and kit for preventing, treating or delaying a cardiovascular disease or disorder in a mammal |
| CN110840895A (en) * | 2013-07-23 | 2020-02-28 | 上海泽生科技开发股份有限公司 | Method for promoting gastrointestinal system motility using vitamin B composition |
| CN110946993A (en) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | Formula of neuregulin preparation |
| CN111803514A (en) * | 2015-06-12 | 2020-10-23 | 上海泽生科技开发股份有限公司 | Method for promoting gastrointestinal system motility using vitamin complex B, C composition |
| CN108079008A (en) * | 2016-11-23 | 2018-05-29 | 上海泽生科技开发股份有限公司 | Promote the compound vitamin composition of gastronintestinal system power |
| CN108567792A (en) | 2017-03-07 | 2018-09-25 | 上海泽生科技开发股份有限公司 | A kind of compound vitamin composition for treating Alzheimer disease |
| CN110403945B (en) * | 2018-04-28 | 2022-11-18 | 上海泽生科技开发股份有限公司 | Composite vitamin composition for promoting gastrointestinal system power and preparation method thereof |
| CN115581699A (en) * | 2018-04-28 | 2023-01-10 | 上海泽生科技开发股份有限公司 | Composite vitamin composition for promoting gastrointestinal system power and preparation method thereof |
| CN112674348A (en) * | 2020-12-23 | 2021-04-20 | 石药集团中诺药业（泰州）有限公司 | Preparation method of B-vitamin buccal tablet and chewable tablet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080213395A1 (en) * | 2004-10-14 | 2008-09-04 | Adventures Plus Pty Ltd | Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins |
| CN104337813A (en) * | 2013-07-23 | 2015-02-11 | 上海泽生科技开发有限公司 | Method using vitamin B composition to promote gastrointestinal system motility |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060280761A1 (en) * | 2002-03-11 | 2006-12-14 | Health Plus International, Inc. | Nanofluidized B-12 composition and process for treating pernicious anemia |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| US20130131007A1 (en) * | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| US20070202215A1 (en) * | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
-
2013
- 2013-07-23 CN CN201911175108.3A patent/CN110840895A/en active Pending
- 2013-07-23 CN CN201310327076.0A patent/CN104337813A/en active Pending
-
2014
- 2014-07-28 WO PCT/CN2014/000712 patent/WO2015010449A1/en active Application Filing
- 2014-07-28 CN CN201480039758.4A patent/CN105636584A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080213395A1 (en) * | 2004-10-14 | 2008-09-04 | Adventures Plus Pty Ltd | Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins |
| CN104337813A (en) * | 2013-07-23 | 2015-02-11 | 上海泽生科技开发有限公司 | Method using vitamin B composition to promote gastrointestinal system motility |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113498862A (en) * | 2021-08-27 | 2021-10-15 | 上海英库商务咨询有限公司 | Diet formula capable of preventing beriberi, herpes and corner inflammation and losing weight |
| CN115105514A (en) * | 2022-06-14 | 2022-09-27 | 邯郸制药股份有限公司 | Pharmaceutical composition for protecting gastric mucosa and treating gastric ulcer and preparation method and application thereof |
| CN115105514B (en) * | 2022-06-14 | 2024-03-15 | 邯郸制药股份有限公司 | Pharmaceutical composition for protecting gastric mucosa and treating gastric ulcer as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110840895A (en) | 2020-02-28 |
| CN104337813A (en) | 2015-02-11 |
| WO2015010449A1 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105636584A (en) | Method for use of vitamin b composition to promote motility of gastrointestinal system | |
| Thomas | Opioid-induced bowel dysfunction | |
| Howden | Management of acid-related disorders in patients with dysphagia | |
| US11759463B2 (en) | Composite vitamin composition promoting gastrointestinal system motility | |
| CN101137378A (en) | Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction | |
| US10881639B2 (en) | Use of composition of multivitamin in preparing drug for stimulating gastrointestinal system motility | |
| EP2142176A1 (en) | Compositions and methods for transmucosal delivery of domperidone | |
| US10350230B2 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
| CN103813792B (en) | Be used for the treatment of the YM-905 of overactive bladder and the combination of saliva stimulant | |
| US20150110865A1 (en) | Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment | |
| EP2849724B1 (en) | Means to facilitate food intake and food retention | |
| CN102319208A (en) | Suspension composition for treating oral mucositis caused by chemoradiotherapy | |
| Hammer et al. | Gastroesophageal reflux and prokinetic agents. | |
| CN110403945B (en) | Composite vitamin composition for promoting gastrointestinal system power and preparation method thereof | |
| WO2020030089A1 (en) | Use of benzodioxole derivative in treatment of disease related to gastrointestinal motility disorder | |
| CN115581699A (en) | Composite vitamin composition for promoting gastrointestinal system power and preparation method thereof | |
| CN101658530B (en) | Medicine combination for treating stomach and duodenum diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160601 |